Dossier assessment
Roxadustat (anaemia) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Roxadustat (anaemia) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Roxadustat (anaemia) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with symptomatic anaemia associated with chronic kidney disease (CKD) who were not previously treated with an erythropoiesis-stimulating agent (ESA) or who are converting from an ESA (conversion of adults with stable ESA pretreatment only when there is a medical indication for a treatment switch)
Added benefit not proven.
Project details
- Project no.
- A21-117
- Commission
- Commission awarded on 06.09.2021 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Haematology
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.